Sign In
Buy NPCE
$15.88
-0.410 (-2.52%)
At Close: Jun 03, 2026
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
09:11am, Thursday, 15'th May 2025
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript
10:33pm, Tuesday, 13'th May 2025
NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
06:25pm, Tuesday, 13'th May 2025
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.32 per share a year ago.
NeuroPace Reports First Quarter 2025 Financial Results
04:05pm, Tuesday, 13'th May 2025
-- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million
Recent Price Trend in NeuroPace (NPCE) is Your Friend, Here's Why
09:50am, Tuesday, 13'th May 2025
If you are looking for stocks that are well positioned to maintain their recent uptrend, NeuroPace (NPCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price
NeuroPace Provides Update on Tariff Status
04:05pm, Monday, 14'th Apr 2025
-- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 --
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
08:00am, Tuesday, 08'th Apr 2025
Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1 Long-term seizure reduction with a median reduction of 82%
MOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending a
NeuroPace Announces Refocusing of Product Portfolio
04:05pm, Wednesday, 02'nd Apr 2025
-- Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 -- -- Maintaining 2025 Revenue Guidance -- -- No Change to Long-Range Plan Expectations of Cash Flow Breakeven by th
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
08:00am, Wednesday, 26'th Mar 2025
MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced tha
NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript
07:45pm, Tuesday, 04'th Mar 2025
NeuroPace, Inc. (NASDAQ:NPCE ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Joel Becker - Chief Executive Officer and Board Member
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Tuesday, 04'th Mar 2025
-- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million --
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference
09:15pm, Monday, 03'rd Mar 2025
MOUNTAIN VIEW, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced tha
NeuroPace to Present at the Leerink Partners Global Healthcare Conference
04:05pm, Monday, 03'rd Mar 2025
MOUNTAIN VIEW, Calif. , March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced th
NeuroPace (NPCE) Surges 5.8%: Is This an Indication of Further Gains?
06:15am, Friday, 21'st Feb 2025
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i
